These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 25072319)
1. Women with the Alzheimer's risk marker ApoE4 lose Aβ-specific CD4⁺ T cells 10-20 years before men. Begum AN; Cunha C; Sidhu H; Alkam T; Scolnick J; Rosario ER; Ethell DW Transl Psychiatry; 2014 Jul; 4(7):e414. PubMed ID: 25072319 [TBL] [Abstract][Full Text] [Related]
2. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4. Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD; JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020 [TBL] [Abstract][Full Text] [Related]
3. Association of β-Amyloid and Apolipoprotein E ε4 With Memory Decline in Preclinical Alzheimer Disease. Lim YY; Kalinowski P; Pietrzak RH; Laws SM; Burnham SC; Ames D; Villemagne VL; Fowler CJ; Rainey-Smith SR; Martins RN; Rowe CC; Masters CL; Maruff PT JAMA Neurol; 2018 Apr; 75(4):488-494. PubMed ID: 29356823 [TBL] [Abstract][Full Text] [Related]
4. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment. Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L; Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868 [TBL] [Abstract][Full Text] [Related]
5. CD4 T cells in immunity and immunotherapy of Alzheimer's disease. Monsonego A; Nemirovsky A; Harpaz I Immunology; 2013 Aug; 139(4):438-46. PubMed ID: 23534386 [TBL] [Abstract][Full Text] [Related]
6. Prediction of Alzheimer's disease diagnosis within 14 years through Aβ misfolding in blood plasma compared to APOE4 status, and other risk factors. Stocker H; Nabers A; Perna L; Möllers T; Rujescu D; Hartmann A; Holleczek B; Schöttker B; Gerwert K; Brenner H Alzheimers Dement; 2020 Feb; 16(2):283-291. PubMed ID: 31611055 [TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid β peptide. Hashimoto T; Serrano-Pozo A; Hori Y; Adams KW; Takeda S; Banerji AO; Mitani A; Joyner D; Thyssen DH; Bacskai BJ; Frosch MP; Spires-Jones TL; Finn MB; Holtzman DM; Hyman BT J Neurosci; 2012 Oct; 32(43):15181-92. PubMed ID: 23100439 [TBL] [Abstract][Full Text] [Related]
8. Genomics of Alzheimer's disease implicates the innate and adaptive immune systems. Li Y; Laws SM; Miles LA; Wiley JS; Huang X; Masters CL; Gu BJ Cell Mol Life Sci; 2021 Dec; 78(23):7397-7426. PubMed ID: 34708251 [TBL] [Abstract][Full Text] [Related]
9. Characterizing Apolipoprotein E ε4 Carriers and Noncarriers With the Clinical Diagnosis of Mild to Moderate Alzheimer Dementia and Minimal β-Amyloid Peptide Plaques. Monsell SE; Kukull WA; Roher AE; Maarouf CL; Serrano G; Beach TG; Caselli RJ; Montine TJ; Reiman EM JAMA Neurol; 2015 Oct; 72(10):1124-31. PubMed ID: 26302353 [TBL] [Abstract][Full Text] [Related]
10. APOE modulates the effect of estrogen therapy on Aβ accumulation EFAD-Tg mice. Kunzler J; Youmans KL; Yu C; Ladu MJ; Tai LM Neurosci Lett; 2014 Feb; 560():131-6. PubMed ID: 24368217 [TBL] [Abstract][Full Text] [Related]
14. Effects of Alzheimer's Disease-Associated Risk Loci on Amyloid-β Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Laiterä T; Paananen J; Helisalmi S; Sarajärvi T; Huovinen J; Laitinen M; Rauramaa T; Alafuzoff I; Remes AM; Soininen H; Haapasalo A; Jääskeläinen JE; Leinonen V; Hiltunen M J Alzheimers Dis; 2017; 55(3):995-1003. PubMed ID: 27802227 [TBL] [Abstract][Full Text] [Related]
15. MHC-independent genetic factors control the magnitude of CD4+ T cell responses to amyloid-β peptide in mice through regulatory T cell-mediated inhibition. Toly-Ndour C; Lui G; Nunes MM; Bruley-Rosset M; Aucouturier P; Dorothée G J Immunol; 2011 Nov; 187(9):4492-500. PubMed ID: 21949026 [TBL] [Abstract][Full Text] [Related]
16. Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Mild Alzheimer's Disease Suggest Disease Modification Potential. Abushakra S; Porsteinsson A; Scheltens P; Sadowsky C; Vellas B; Cummings J; Gauthier S; Hey JA; Power A; Wang P; Shen L; Tolar M J Prev Alzheimers Dis; 2017; 4(3):149-156. PubMed ID: 29182706 [TBL] [Abstract][Full Text] [Related]
17. Gene vaccination to bias the immune response to amyloid-beta peptide as therapy for Alzheimer disease. Qu B; Rosenberg RN; Li L; Boyer PJ; Johnston SA Arch Neurol; 2004 Dec; 61(12):1859-64. PubMed ID: 15596606 [TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein E epsilon 4 is associated with an increased vulnerability to cell death in Alzheimer's disease. Frey C; Bonert A; Kratzsch T; Rexroth G; Rösch W; Müller-Spahn F; Maurer K; Müller WE; Eckert A J Neural Transm (Vienna); 2006 Nov; 113(11):1753-61. PubMed ID: 16736246 [TBL] [Abstract][Full Text] [Related]